The EPO published patent EP3946295A1 for combinations of iadademstat with other therapeutic agents for treating cancer. Iadademstat is an LSD1 (lysine-specific histone demethylase 1A) inhibitor. The patent covers pharmaceutical compositions combining iadademstat with additional therapeutic agents for use in cancer therapy, with applications potentially extending to multiple cancer types. The patent designation covers 35 European states including major markets such as Germany, France, UK, Italy, and Spain.

This is an informational patent publication with no compliance deadlines or required actions for third parties. Pharmaceutical companies and researchers developing competing cancer therapies should review this patent to assess potential freedom-to-operate implications. Companies working with LSD1 inhibitors in oncology should evaluate whether their development activities may infringe this granted patent.